Immunogen (NASDAQ: IMGN) reported Q3 EPS of ($0.37), $0.05 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $19.7 million versus the consensus estimate of $23.02 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.